Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
Crossref DOI link: https://doi.org/10.1186/s12885-017-3527-7
Published Online: 2017-08-15
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Négrier, Sylvie
Pérol, David
Bahleda, Rastislav
Hollebecque, Antoine
Chatelut, Etienne
Boyle, Helen
Cassier, Philippe
Metzger, Séverine
Blanc, Ellen
Soria, Jean-Charles
Escudier, Bernard
Funding for this research was provided by:
GlaxoSmithKline
Roche
